Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies-Reference-Cited by-同舟云学术

Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies

Published:2020-12-03 Issue:30 Volume:20 Page:2762-2776
ISSN:1568-0266
Container-title:Current Topics in Medicinal Chemistry
language:en
Short-container-title:CTMC

Author:

Zhao Xin¹,Ye Yun¹,Ge Shuyu²,Sun Pingping²,Yu Ping²

Affiliation:

1. Department of Pharmacy, Beilun People's Hospital, Ningbo 315800, Zhejiang Province, China

2. Department of Pharmacy, Tongde Hospital of Zhejiang Province, Hangzhou 310012, Zhejiang Province, China

Abstract

Central nervous system (CNS) cancers are among the most common and treatment-resistant diseases. The main reason for the low treatment efficiency of the disorders is the barriers against targeted delivery of anticancer agents to the site of interest, including the blood-brain barrier (BBB) and blood-brain tumor barrier (BBTB). BBB is a strong biological barrier separating circulating blood from brain extracellular fluid that selectively and actively prevents cytotoxic agents and majority of anticancer drugs from entering the brain. BBB and BBTB are the major impediments against targeted drug delivery into CNS tumors. Nanotechnology and its allied modalities offer interesting and effective delivery strategies to transport drugs across BBB to reach brain tissue. Integrating anticancer drugs into different nanocarriers improves the delivery performance of the resultant compounds across BBB. Surface engineering of nanovehicles using specific ligands, antibodies and proteins enhances the BBB crossing efficacy as well as selective and specific targeting to the target cancerous tissues in CNS tumors. Multifunctional nanoparticles (NPs) have brought revolutionary advances in targeted drug delivery to brain tumors. This study reviews the main anatomical, physiological and biological features of BBB and BBTB in drug delivery and the recent advances in targeting strategies in NPs-based drug delivery for CNS tumors. Moreover, we discuss advances in using specific ligands, antibodies, and surface proteins for designing and engineering of nanocarriers for targeted delivery of anticancer drugs to CNS tumors. Finally, the current clinical applications and the perspectives in the targeted delivery of therapeutic molecules and genes to CNS tumors are discussed.

Publisher

Bentham Science Publishers Ltd.

Subject

Drug Discovery,General Medicine

Reference170 articles.

1. Roth G.A.; Abate D.; Abate K.H.; Abay S.M.; Abbafati C.; Abbasi N.; Abbastabar H.; Abd-Allah F.; Abdela J.; Abdelalim A.; Abdollahpour I.; Abdulkader R.S.; Abebe H.T.; Abebe M.; Abebe Z.; Abejie A.N.; Abera S.F.; Abil O.Z.; Abraha H.N.; Abrham A.R.; Abu-Raddad L.J.; Accrombessi M.M.K.; Acharya D.; Adamu A.A.; Adebayo O.M.; Adedoyin R.A.; Adekanmbi V.; Adetokunboh O.O.; Adhena B.M.; Adib M.G.; Admasie A.; Afshin A.; Agarwal G.; Agesa K.M.; Agrawal A.; Agrawal S.; Ahmadi A.; Ahmadi M.; Ahmed M.B.; Ahmed S.; Aichour A.N.; Aichour I.; Aichour M.T.E.; Akbari M.E.; Akinyemi R.O.; Akseer N.; Al-Aly Z.; Al-Eyadhy A.; Al-Raddadi R.M.; Alahdab F.; Alam K.; Alam T.; Alebel A.; Alene K.A.; Alijanzadeh M.; Alizadeh-Navaei R.; Aljunid S.M.; Alkerwi A.; Alla F.; Allebeck P.; Alonso J.; Altirkawi K.; Alvis-Guzman N.; Amare A.T.; Aminde L.N.; Amini E.; Ammar W.; Amoako Y.A.; Anber N.H.; Andrei C.L.; Androudi S.; Animut M.D.; Anjomshoa M.; Ansari H.; Ansha M.G.; Antonio C.A.T.; Anwari P.; Aremu O.; Ärnlöv J.; Arora A.; Arora M.; Artaman A.; Aryal K.K.; Asayesh H.; Asfaw E.T.; Ataro Z.; Atique S.; Atre S.R.; Ausloos M.; Avokpaho E.F.G.A.; Awasthi A.; Quintanilla B.P.A.; Ayele Y.; Ayer R.; Azzopardi P.S.; Babazadeh A.; Bacha U.; Badali H.; Badawi A.; Bali A.G.; Ballesteros K.E.; Banach M.; Banerjee K.; Bannick M.S.; Banoub J.A.M.; Barboza M.A.; Barker-Collo S.L.; Bärnighausen T.W.; Barquera S.; Barrero L.H.; Bassat Q.; Basu S.; Baune B.T.; Baynes H.W.; Bazargan-Hejazi S.; Bedi N.; Beghi E.; Behzadifar M.; Behzadifar M.; Béjot Y.; Bekele B.B.; Belachew A.B.; Belay E.; Belay Y.A.; Bell M.L.; Bello A.K.; Bennett D.A.; Bensenor I.M.; Berman A.E.; Bernabe E.; Bernstein R.S.; Bertolacci G.J.; Beuran M.; Beyranvand T.; Bhalla A.; Bhattarai S.; Bhaumik S.; Bhutta Z.A.; Biadgo B.; Biehl M.H.; Bijani A.; Bikbov B.; Bilano V.; Bililign N.; Bin Sayeed M.S.; Bisanzio D.; Biswas T.; Blacker B.F.; Basara B.B.; Borschmann R.; Bosetti C.; Bozorgmehr K.; Brady O.J.; Brant L.C.; Brayne C.; Brazinova A.; Breitborde N.J.K.; Brenner H.; Briant P.S.; Britton G.; Brugha T.; Busse R.; Butt Z.A.; Callender C.S.K.H.; Campos-Nonato I.R.; Campuzano Rincon J.C.; Cano J.; Car M.; Cárdenas R.; Carreras G.; Carrero J.J.; Carter A.; Carvalho F.; Castañeda-Orjuela C.A.; Castillo Rivas J.; Castle C.D.; Castro C.; Castro F.; Catalá-López F.; Cerin E.; Chaiah Y.; Chang J-C.; Charlson F.J.; Chaturvedi P.; Chiang P.P-C.; Chimed-Ochir O.; Chisumpa V.H.; Chitheer A.; Chowdhury R.; Christensen H.; Christopher D.J.; Chung S-C.; Cicuttini F.M.; Ciobanu L.G.; Cirillo M.; Cohen A.J.; Cooper L.T.; Cortesi P.A.; Cortinovis M.; Cousin E.; Cowie B.C.; Criqui M.H.; Cromwell E.A.; Crowe C.S.; Crump J.A.; Cunningham M.; Daba A.K.; Dadi A.F.; Dandona L.; Dandona R.; Dang A.K.; Dargan P.I.; Daryani A.; Das S.K.; Das Gupta R.; Das Neves J.; Dasa T.T.; Dash A.P.; Davis A.C.; Davis Weaver N.; Davitoiu D.V.; Davletov K.; De La Hoz F.P.; De Neve J-W.; Degefa M.G.; Degenhardt L.; Degfie T.T.; Deiparine S.; Demoz G.T.; Demtsu B.B.; Denova-Gutiérrez E.; Deribe K.; Dervenis N.; Des Jarlais D.C.; Dessie G.A.; Dey S.; Dharmaratne S.D.; Dicker D.; Dinberu M.T.; Ding E.L.; Dirac M.A.; Djalalinia S.; Dokova K.; Doku D.T.; Donnelly C.A.; Dorsey E.R.; Doshi P.P.; Douwes-Schultz D.; Doyle K.E.; Driscoll T.R.; Dubey M.; Dubljanin E.; Duken E.E.; Duncan B.B.; Duraes A.R.; Ebrahimi H.; Ebrahimpour S.; Edessa D.; Edvardsson D.; Eggen A.E.; El Bcheraoui C.; El Sayed Zaki M.; El-Khatib Z.; Elkout H.; Ellingsen C.L.; Endres M.; Endries A.Y.; Er B.; Erskine H.E.; Eshrati B.; Eskandarieh S.; Esmaeili R.; Esteghamati A.; Fakhar M.; Fakhim H.; Faramarzi M.; Fareed M.; Farhadi F.; Farinha C.S.E.; Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the global burden of disease study 2017. Lancet 2018,392,1736-1788

2. Smith M.A.; Reaman G.H.; Remaining challenges in childhood cancer and newer targeted therapeutics. Pediatr Clin North Am 2015,62(1),301-312

3. Perkins A.; Liu G.; Primary brain tumors in adults: diagnosis and treatment. Am Fam Physician 2016,93(3),211-217

4. Chinot O.L.; Wick W.; Mason W.; Henriksson R.; Saran F.; Nishikawa R.; Carpentier A.F.; Hoang-Xuan K.; Kavan P.; Cernea D.; Brandes A.A.; Hilton M.; Abrey L.; Cloughesy T.; Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014,370(8),709-722

5. Aldape K.; Brindle K.M.; Chesler L.; Chopra R.; Gajjar A.; Gilbert M.R.; Gottardo N.; Gutmann D.H.; Hargrave D.; Holland E.C.; Jones D.T.W.; Joyce J.A.; Kearns P.; Kieran M.W.; Mellinghoff I.K.; Merchant M.; Pfister S.M.; Pollard S.M.; Ramaswamy V.; Rich J.N.; Robinson G.W.; Rowitch D.H.; Sampson J.H.; Taylor M.D.; Workman P.; Gilbertson R.J.; Challenges to curing primary brain tumours. Nat Rev Clin Oncol 2019,16(8),509-520

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Delivery to the Brain: Targeting Technologies to Deliver Therapeutics to Brain Lesions;Targeted Drug Delivery;2022-11-18

2. Micro/Nanosystems for Magnetic Targeted Delivery of Bioagents;Pharmaceutics;2022-05-26

3. Application of Non-Viral Vectors in Drug Delivery and Gene Therapy;Polymers;2021-09-28

4. Application of New Radiosensitizer Based on Nano-Biotechnology in the Treatment of Glioma;Frontiers in Oncology;2021-03-22